Can Neko Health really scale like Spotify?
In our updated market reports, you will find everything you need
SUMMARY
Neko Health can become a major global preventive-health company, but it cannot scale like Spotify under its current one-hour, clinic-based delivery model.
The company has already moved past the experimental-clinic stage. More than 100,000 completed scans, eight operating clinics and over $1 billion raised show that Neko is building an international healthcare network rather than testing a boutique concept.
Demand is stronger than the headline waitlist alone suggests. The more convincing figure is the roughly 75% prepaid rebooking rate, because customers are paying for another scan rather than simply registering interest.
Neko’s recent growth is unusually fast for an in-person medical service. Completed scans have increased more than tenfold since early 2025, while the clinic format has been copied from Stockholm into London, Manchester and Birmingham.
The physical model still sets a hard ceiling. One million annual scans would require roughly 34 large clinics at maximum stated capacity, while ten million would require about 334.
A large clinic can generate meaningful revenue. At the current UK price, a 30,000-scan site could produce almost £9 million a year, but Neko has not disclosed enough about utilization, payroll, construction costs or site payback to prove attractive clinic-level profits.
The medical product appears useful, not merely fashionable. In Neko’s published Stockholm cohort, 1.2% of customers had a previously unknown life-threatening condition and 6.4% received an important actionable finding.
The trade-off is follow-up burden. About one in twenty customers underwent additional testing and was eventually cleared, which would translate into tens of thousands of extra workups at million-customer scale.
Neko’s strongest advantage is the integration of proprietary devices, on-site analysis, software, clinical workflow and repeat data. Competitors can copy individual tests more easily than they can reproduce the full one-hour experience.
New York will be the decisive operating test. The US offers deeper consumer spending and a large preventive-health market, but also more regulatory friction, medical liability and fragmented follow-up care.
Employers, insurers and operating partners could push Neko beyond affluent self-paying customers. So far, however, the company has not disclosed a large institutional contract or reimbursement channel that changes the economics.
Our conclusion is that several million annual customers look plausible, tens of millions would require cheaper formats and partner-run distribution, and hundreds of millions are unrealistic without a radically different model. Neko has proved demand and fast clinic replication; it has not yet proved software-like economics.
Why are people calling Neko Health the “Spotify of healthcare”?
The comparison has become credible now because Neko Health has moved well beyond one experimental clinic and is spending serious money on an international rollout.
Neko’s latest fundraising announcement says more than 100,000 people have completed a scan. The company currently operates eight clinics across Sweden and the United Kingdom, with New York due to become its first US location.
The financing has grown just as quickly. Neko raised $65 million in 2023, $260 million in early 2025 and another $700 million lately. That adds up to just over $1 billion. The Financial Times reported that the newest round valued Neko at nearly $7 billion, roughly four times its valuation at the previous round.
Daniel Ek’s presence explains the nickname, but the comparison now goes deeper than having the same co-founder. Neko is trying to turn a fragmented, unpleasant healthcare task into a simple consumer experience, then reproduce it under one global brand. Spotify did something similar with music. The difficult part is that Neko still needs a clinic, medical equipment and clinical staff every time someone uses the service.
If you want more recent data on this point, please see our latest preventive health screening market report.
What would scaling like Spotify actually look like?
In practical terms, Neko would need to grow its customer base much faster than its clinics, staffing costs and medical complexity.
Spotify’s latest filed results show 761 million monthly active users, 293 million paying subscribers and a presence in 184 markets. A new listener can start within minutes without Spotify building a listening room or scheduling a professional for that person.
A Neko customer currently spends about an hour inside a physical clinic. The visit includes skin imaging, cardiovascular measurements, a blood draw, on-site analysis and a consultation with a clinician. Expansion therefore requires rooms, machines, nurses, doctors, laboratory processes and local regulatory approval.
There are three versions of the Spotify comparison. A globally recognized consumer brand looks plausible today, millions of recurring customers are possible, and digital-style economics remain far away under Neko’s current delivery model.
| Measure | Spotify today | Neko Health today | What Neko must prove |
|---|---|---|---|
| Reach | 761 million monthly users | A six-figure completed scan base | Demand can grow from thousands to millions |
| Geography | 184 markets | Eight operating clinics in two countries | The same care model works across medical systems |
| Customer frequency | Often daily | Mainly once a year | People keep returning after several healthy scans |
| Delivery | Digital | One-hour clinic visit | Volume rises faster than rooms and staff |
| Expansion cost | Limited physical capacity per user | New sites, devices and clinicians | Software and automation carry more of the growth |
Is Neko Health growing unusually fast right now?
Yes, Neko’s recent growth is exceptional for a business that has to examine every customer in person.
When Neko announced its Series B in early 2025, it had completed 10,000 scans across Stockholm and London. The latest company figure is above 100,000, so its total scan count has grown more than tenfold in roughly a year and a half. Neko also said it delivered six times more scans in 2025 than in 2024.
The clinic network has grown almost as fast. Neko now has two Stockholm clinics and six in the UK, covering four London locations plus Manchester and Birmingham. It started with one Stockholm site in 2023 and entered Britain in late 2024. Few private medical brands open that many sites, train hundreds of clinical employees and preserve one standardized customer journey so quickly.
The growth also appears to extend beyond wealthy central London. Manchester opened with capacity for 20,000 annual scans, Birmingham followed with capacity for 25,000, and thousands had reportedly joined each local waitlist before opening. That gives us more confidence than another fashionable clinic in Marylebone would have.
Nearly all this growth has come from adding physical capacity. Neko has shown that its clinic format can be copied across cities, while customer volume still rises with the number of scanning rooms and medical teams.
Is Neko Health’s demand as strong as it looks?
Neko’s demand is real today, although a waitlist signup and a prepaid return visit tell us very different things.
A waitlist signup only shows interest. Neko now has more than 350,000 registrations, but the better evidence comes from people booking once clinics open. Vogue Business reported that its first London appointments disappeared within ten minutes and that the UK queue later remained around six figures.
The 75% prepaid rebooking rate is much more persuasive. Customers are handing over money for another scan rather than merely saying they enjoyed the first one. Neko reported 80% when it had completed its first 10,000 scans, so retention has softened only slightly as the customer base became much larger.
Registrations currently outnumber completed scans by roughly 3.5 to one. That leaves plenty of demand to serve, but we still need the missing conversion rate: when Neko opens near registered users, how many actually pay? We also need longer cohorts. Returning once after an interesting first scan is easier than paying for a fourth or fifth year of mostly normal results.
Neko has clearly found a large group of affluent customers who want this service. We still do not know whether ordinary households will pay every year after several reassuring scans.
If you want more recent data on this point, please see our latest preventive health screening market report.
Can one Neko Health clinic make enough money?
A busy Neko clinic can produce substantial revenue, but the company has not published enough cost data to show attractive clinic-level profits.
Neko says its Spitalfields site can deliver up to 30,000 scans per year. At the current UK fee, full utilization would produce about £8.97 million in annual scan revenue. Manchester can handle 20,000 scans and Birmingham 25,000, equivalent to maximum scan revenue of roughly £5.98 million and £7.48 million.
Those are respectable figures for individual healthcare sites. They also show the amount of infrastructure required. One million annual scans would need about 34 Spitalfields-sized clinics. Ten million would need roughly 334.
We still cannot tell whether these sites make good money. Neko has not disclosed construction costs, equipment spending, utilization by clinic, payroll per scan, customer acquisition costs or how long a new site takes to repay its setup cost. The company also includes follow-up reviews, referral letters and some specialist work in the original price.
The capacity figures show that one large clinic can become a meaningful business, while profitability remains unproven. Neko’s recent funding gives it room to build before every location pays for itself, and that same cash can hide weak economics for quite a while.
| Annual scan volume | Large clinics required at maximum site capacity | Gross scan revenue at the current UK price | What it would represent |
|---|---|---|---|
| 30,000 | 1 | £8.97 million | One large city clinic |
| 1 million | About 34 | £299 million | A major international network |
| 10 million | About 334 | £2.99 billion | One of the world’s largest clinic chains |
| 100 million | About 3,334 | £29.9 billion | Medical infrastructure on a vast scale |
Can Neko scan many more people without rushing the medicine?
Neko can process more people as its software improves, but clinicians still limit how cheap and fast the service can become.
The company has built four main proprietary devices for skin imaging, circulation and heart assessment. Its system takes more than 2,000 high-resolution skin images, processes blood on site and brings the results together before the consultation. More recently, it added body-composition measurements and wearable data from Apple Health without extending the one-hour visit.
That engineering can remove repetitive work. Cameras can capture the same angles every time, algorithms can highlight unusual patterns, and software can prepare a clear review for the clinician. The next generation of Neko equipment is being rolled out in Stockholm with higher-fidelity data and a redesigned scan room.
The medical workload remains substantial. Neko says its clinicians typically see around nine members a day. When the company had four UK clinics, it employed more than 350 medical staff there, including general practitioners, cardiologists, dermatologists and nurses. Some of those employees support follow-ups and central operations, so the figure cannot be divided neatly by appointment. Even so, Neko is plainly running a labor-intensive service.
The number to watch is clinician time per completed customer. If software lets one doctor safely review several scans in parallel and spend less time on routine cases, margins can improve sharply. If each visit continues to need a long personal review plus specialist backup, the company will scale more like a premium clinic group than a technology platform.
Is Neko Health cheap enough for ordinary people?
At its current £299 UK price, Neko is affordable beside luxury health screening but expensive as a mass annual habit.
The price sits in a clever middle ground. It is close to Function Health’s annual laboratory membership, which starts at $365, and far below private whole-body MRI services that can cost well above $1,000. Neko adds a polished clinic, same-visit blood results, skin mapping, cardiovascular checks and a clinician consultation.
For many customers, the fee feels reasonable once. Paying it every year is a different decision. A couple would spend £598 annually before any treatment, medication or follow-up outside Neko. That is manageable for affluent professionals and difficult for a large share of households.
Neko’s chief executive has described the current product as “affordable luxury.” Vogue Business reported that customers average about 44 years old and that the early biohacking-heavy audience has broadened. Those details suggest a sizeable premium market, perhaps millions of people across rich cities, rather than immediate mass access.
The price can fall through automation, cheaper clinic formats or narrower scan packages. Employers and insurers could also pay on behalf of users. Until one of those routes becomes meaningful, Neko will remain far more accessible than elite longevity medicine and far less universal than Spotify.
Does a Neko Health scan actually catch dangerous disease?
Yes, Neko’s published Stockholm results show a meaningful number of serious diagnoses, including cancers and heart conditions that customers did not know they had.
In its second operating year, Neko analysed 4,362 scans. It found a previously unknown life-threatening condition in 54 people, or about one in every 81 scanned. The cases included 25 melanomas, 19 severe cardiovascular conditions, eight severe metabolic conditions and two serious blood diseases.
A further 174 people, or 4%, received a significant diagnosis requiring medical attention. Another 52 had an early or reversible condition. Added together, Neko classified 6.4% of customers as having an important actionable finding.
At one million scans, the same detection rate would mean about 12,000 people with potentially life-threatening findings. The actual rate may change in different countries and customer groups, but the Stockholm cohort is already large enough to show that Neko finds more than rare curiosities.
These figures come from Neko’s own observational report rather than an independent controlled study. We can trust the documented diagnoses more than broader claims about lives saved, because we do not know what ordinary care would have found later or how outcomes changed.
| Result in Neko’s 4,362-scan cohort | People | Share of scans | Examples |
|---|---|---|---|
| No further medical follow-up | 3,547 | 81.3% | Healthy or already controlled |
| Previously unknown life-threatening condition | 54 | 1.2% | Melanoma, severe heart disease, leukemia |
| Significant condition | 174 | 4.0% | Hypertension, valve disease, diabetes |
| Early or reversible condition | 52 | 1.2% | Prediabetes, elevated blood pressure |
| Cleared after further testing | 217 | About 5% | Skin, blood or cardiovascular checks |
How many Neko customers get worried for nothing?
About one in twenty people in Neko’s published Stockholm cohort needed extra testing and was then cleared, which is large enough to take seriously.
Neko referred 18.7% of the 4,362 customers for some form of follow-up. The final results included the serious and treatable diagnoses described above, while 217 people, or 4.9% of the full group, were cleared after extra skin, laboratory or cardiovascular checks. Another 27 were still being investigated, and 291 chose an outside provider or did not complete Neko’s follow-up.
A negative follow-up does not mean the initial concern was careless. Screening works by investigating uncertain findings, and some harmless cases must be checked to find the dangerous ones. The practical burden grows quickly, though. A 4.9% clearance rate would create 49,000 additional workups per million scans.
Medical guidelines remain cautious for that reason. The US Preventive Services Task Force recommends against ECG screening for low-risk adults without symptoms and says evidence is insufficient for medium- or high-risk adults. For routine visual skin screening of people without symptoms, it also says the overall balance of benefits and harms is still uncertain.
Neko may perform better than isolated screening tests because it combines measurements, reviews findings internally and tracks changes over time. Its long-term credibility will depend on publishing how many biopsies, specialist visits and procedures follow each scan, alongside the serious conditions found.
If you want more recent data on this point, please see our latest preventive health screening market report.
Do people get healthier after a second Neko scan?
Neko’s early repeat-scan data is encouraging, but we cannot yet tell how much of the improvement came from the service.
The company studied 1,469 Stockholm members who returned roughly one year later. Across the full group, blood pressure, cholesterol and blood sugar improved by statistically significant amounts, while weight stayed broadly stable. People with hypertension, prediabetes or diabetes showed the clearest gains.
A smaller group gives us another clue. Among 113 returning members who had previously received a severe or significant diagnosis, 87, or 77%, were healthy or had the condition under control at their next scan. Some had received treatment, while others changed habits after learning about their risk.
Neko openly states that this was not a controlled scientific study. Returners selected themselves, knew their first results and may be more motivated than customers who did not come back. Medication, ordinary doctors and lifestyle changes all contributed, and there was no matched group showing what would have happened without Neko.
Our reading today is that Neko appears useful for finding risks and prompting action. Evidence that annual scanning itself improves long-term health, reduces hospital admissions or extends life will take larger independent studies and several more years.
What does Neko have that competitors cannot easily copy?
Neko’s hardest-to-copy advantage today is the way its devices, clinic workflow, medical team and growing data set work together.
Competitors can reproduce individual pieces. Function Health can order broad blood panels without running elaborate clinics. Prenuvo and Ezra can offer much deeper internal imaging through MRI. Dermatology software can map moles, while ordinary private clinics already perform ECGs, blood pressure checks and doctor consultations.
Neko puts many of these tasks into one hour at one price. It designs and assembles its own devices in Stockholm, operates on-site laboratories, controls the app and trains clinicians around one repeatable process. Around three-quarters of the data in each scan reportedly comes from Neko-built equipment.
The data becomes more valuable as customers return. The Financial Times reported that one scan produces roughly 15 gigabytes and that more than 90% of customers consent to AI use. Applied to the completed scan base, that points to a data collection on the order of 1.5 petabytes, although storage methods and scan versions will affect the real figure.
Neko also added body composition and wearable integration lately, giving doctors information about sleep, movement and recovery between annual visits. This makes the product harder to reduce to a single body scan.
This advantage could shrink. Medical feedback arrives slowly, customer groups may be biased toward affluent Europeans, and large healthcare providers can buy many similar technologies. Neko’s lead will last only if its integrated system produces fewer mistakes, faster visits and better outcomes than competitors assembling comparable tests.
Will New York prove that Neko works outside Europe?
New York is now Neko’s most important test because the US offers much more spending power and much more operational friction.
Demand should be strong. The American market already supports executive health checks, longevity memberships, laboratory platforms and whole-body MRI companies. Vogue Business reported that some US customers already travel to London for Neko and put the planned New York price at around $500, a figure Neko has yet to confirm.
Neko initially said the New York clinic would open in spring, while its current location page now says fall. The company has not explained the shift, leaving the cause unclear. Even so, the moved timeline shows how device approvals, clinical hiring, laboratory rules and medical liability can slow a healthcare rollout.
Neko has prepared seriously. It hired former Amazon Health executive Sunita Mishra as chief medical officer, secured the $700 million round and says New York will be its largest clinic. Its latest announcement also refers to additional US cities rather than a one-location experiment.
Bookings will tell us whether Americans want the product. The bigger test comes after opening: price, utilization, clinician productivity, follow-up costs and whether Neko can reproduce the same calm one-hour experience inside a fragmented healthcare system.
If you want more recent data on this point, please see our latest preventive health screening market report.
Can employers and insurers make Neko mainstream?
Employers and insurers offer Neko its clearest path beyond wealthy consumers, but there is currently little proof that either channel is ready to pay at scale.
A consumer may buy a scan for reassurance or curiosity. An employer needs evidence that the benefit improves recruitment, reduces absence or catches expensive illness early. An insurer will compare any savings from prevention with the cost of the scan and all the extra tests it triggers.
Neko’s chief executive has said the company hopes its health data will attract employers, insurers and health systems. That is a credible ambition because annual monitoring creates the kind of year-by-year evidence those buyers want. The recent wearable integration also gives Neko more information between clinic visits.
So far, Neko has not announced a large employer contract, broad insurance reimbursement or a public-health partnership that brings in substantial customer volume. Direct payment still appears to drive the business.
Institutional buyers could change the economics quickly. A few large contracts can fill clinics, lower acquisition costs and make the service available to people who would never pay for it themselves. They can also walk away quickly if independent studies fail to show savings.
What has to change before Neko reaches millions of customers?
Neko needs to make the scalable parts of its system grow faster than the physical appointment.
First, each scanning room must handle more people without weakening the consultation or increasing mistakes. Automated capture, parallel clinical review and shorter personalized protocols could push throughput beyond today’s format.
Second, Neko will probably need partners. Owning several hundred clinics is possible, while owning several thousand would turn the company into a huge medical landlord and employer. Hospitals, insurers or local operators could run Neko equipment under licence, although that would make quality control harder.
Third, the product needs more price levels. A healthy low-risk customer may need a full visit less often, with wearable monitoring, blood tests or targeted checks in between. Higher-risk customers could receive the complete scan every year. That would use expensive clinic capacity more intelligently.
Fourth, Neko needs independent outcome and cost studies. Its current research programme covers cardiovascular disease, microcirculation and early detection, but major payers will want proof that the full service prevents enough serious illness to justify the total cost.
Finally, the company must show mature clinic economics. Until Neko publishes utilization, profit per scan and how long each clinic takes to repay its setup cost, we cannot tell whether the technology is making expansion cheaper or simply supporting an attractive service with expensive infrastructure.
Can Neko Health really scale like Spotify?
No. Neko Health can become a major global preventive-health company, but its current clinic model cannot reproduce Spotify’s speed, reach or cost structure.
There is plenty to like already. Neko has increased scan volume at an unusual pace, built a recognizable consumer brand, kept prepaid rebooking near three-quarters, expanded beyond capital-city early adopters and found serious undiagnosed conditions in a meaningful share of customers. Its proprietary equipment and year-by-year data give it more leverage than an ordinary private clinic chain.
The Spotify comparison breaks when we follow the next customer. Spotify can add that person through software. Neko must provide a room, equipment, blood processing and medical judgment. Hundreds of successful clinics could create a multibillion-dollar company, yet they would still form a healthcare network rather than a digital distribution engine.
Our judgment is that Neko can plausibly reach several million annual customers and become the best-known global brand in technology-led preventive checks. Tens of millions would require cheaper formats, payer support and partner-run locations. Reaching hundreds of millions under the present one-hour model is unrealistic.
Neko will earn the Spotify label only when its devices, software and clinical protocols can spread much faster than its own clinics. Today, the company has proved demand and rapid replication. Profitable clinics, long-term health benefits and distribution through partners are the parts still waiting for proof.
If you want more recent data on this point, please see our latest preventive health screening market report.
OUR METHODOLOGY
This analysis tests whether Neko Health can scale in a way that meaningfully resembles Spotify. We treated the comparison as an operating question rather than a founder metaphor and examined demonstrated demand, repeat usage, clinic replication, physical throughput, clinical labor, site economics, affordability, medical value and possible distribution through employers, insurers or operating partners.
We distinguished three different meanings of scale: building a global consumer brand, serving millions of recurring customers and achieving software-like economics. Neko may accomplish the first two without accomplishing the third.
We prioritized completed scans over waitlist registrations, prepaid rebookings over expressions of interest, operating clinics over announced expansion and documented diagnoses over broad claims about lives saved. Company-reported figures were used when they provided the most direct operating evidence, but we separated what those figures demonstrate from what they merely suggest.
Clinic-capacity figures and current pricing were translated into simple scale scenarios to show the physical requirements behind the growth story. These calculations are not revenue forecasts. We did not infer clinic margins because Neko has not disclosed utilization by site, construction costs, equipment spending, payroll per scan, customer acquisition costs or site payback periods.
Medical-value claims were assessed using Neko’s published Stockholm findings and repeat-scan data. We treated documented diagnoses as stronger evidence than claims about long-term health improvement, because the available studies are observational and do not include a matched control group.
Screening benefits were considered alongside follow-up burden. We compared Neko’s reported referrals and cleared follow-ups with US Preventive Services Task Force guidance on electrocardiography and visual skin-cancer screening in asymptomatic adults.
Competitive positioning was assessed by comparing Neko’s integrated clinic model with laboratory memberships, whole-body MRI providers and conventional private screening. The core question was not whether competitors can copy individual tests, but whether they can reproduce Neko’s combination of proprietary devices, on-site analysis, software, clinical workflow and repeat data.
Key sources include Neko Health’s Series C announcement, the Financial Times on valuation, funding and data scale, Neko Health’s Series B announcement, Neko Health’s current locations page, the Spitalfields capacity announcement, the Manchester opening announcement, the Birmingham opening announcement, Neko Health’s scan overview, Neko Health’s 4,362-scan Stockholm report, its repeat-scan results, its body-composition and wearable-data announcement, Spotify Investor Relations, Vogue Business on customer demand and positioning, the US Preventive Services Task Force on skin-cancer screening, its recommendation on ECG screening, Function Health’s official pricing, Prenuvo’s official offering and Ezra’s official pricing.
Related blog posts
- Who is winning the race in full-body scans?
